Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Wang S, Liechty B, Patel S, Weber JS, Hollmann TJ, Snuderl M, et al. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol. 2018;138(1):183-190.

Circosta P, Elia AR, Landra I, Machiorlatti R, Todaro M, Aliberti S, et al. Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. Oncoimmunology. 2018;7(4):e1341032.

Lange KR, Fischer C, Rajappa P, Connors S, Pisapia D, Greenfield JP, et al. Rapid autopsy of a patient with recurrent anaplastic ependymoma. Palliat Support Care. 2018;16(2):238-242.

Graff RE, Ahearn TU, Pettersson A, Ebot EM, Gerke T, Penney KL, et al. Height, Obesity, and the Risk of -Defined Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018;27(2):193-200.

Legault K, Schunemann H, Hillis C, Yeung C, Akl EA, Carrier M, et al. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost. 2018.

Mechery V, Hernandez T, Mathew AT, Wanchoo R, Seshan SV, Jhaveri KD, et al. Nephropathology Education During Nephrology Fellowship Training in the United States. Kidney Int Rep. 2018;3(2):236-241.

Haffner MC, Taheri D, Luidy-Imada E, Palsgrove DN, Eich M-, Netto GJ, et al. Hypomethylation, endogenous retrovirus expression, and interferon signaling in testicular germ cell tumors. Proc Natl Acad Sci U S A. 2018;115(37):E8580-E8582.

Li W, Xia S, Aronova A, Min IM, Verma A, Scognamiglio T, et al. CHL1 expression differentiates Hürthle cell carcinoma from benign Hürthle cell nodules. J Surg Oncol. 2018;118(6):1042-1049.

Debnath S, Yallowitz AR, McCormick J, Lalani S, Zhang T, Xu R, et al. Discovery of a periosteal stem cell mediating intramembranous bone formation. Nature. 2018;562(7725):133-139.

Ravi R, Noonan KA, Pham V, Bedi R, Zhavoronkov A, Ozerov IV, et al. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy. Nat Commun. 2018;9(1):741.